A Bibliometric Analysis of Research Trends in Febrile Neutropenia

Background: Febrile neutropenia (FN) is a serious and potentially life-threatening complication in patients undergoing chemotherapy, associated with significant morbidity, mortality, and healthcare burden. Over the past two decades, research in this field has expanded considerably, reflecting advances in oncology and supportive care. Bibliometric analysis provides a systematic approach to evaluating the structure and evolution of scientific literature.
Objective: This study aimed to analyze global research trends, key contributors, and emerging themes in febrile neutropenia using bibliometric methods.

Febrile neutropenia; Neutropenic fever; Bibliometric analysis; Oncology

1. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–3051. [Google Scholar] [Crossref]

2. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2011;52(4):e56–e93. [Google Scholar] [Crossref]

3. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients. Clin Infect Dis. 2002;34(6):730–751. [Google Scholar] [Crossref]

4. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks and consequences. Cancer. 2004;100(2):228–237. [Google Scholar] [Crossref]

5. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for G-CSF use. Eur J Cancer. 2011;47(1):8–32. [Google Scholar] [Crossref]

6. Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam monotherapy vs combination therapy for febrile neutropenia. Cochrane Database Syst Rev. 2013;6:CD003038. [Google Scholar] [Crossref]

7. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela JA, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia. J Clin Oncol. 2015;33(5):465–471. [Google Scholar] [Crossref]

8. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia. Cancer. 2007;106(10):2258–2266. [Google Scholar] [Crossref]

9. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults. J Clin Oncol. 2018;36(14):1443–1453. [Google Scholar] [Crossref]

10. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis in neutropenic patients. J Clin Oncol. 2013;31(6):794–810. [Google Scholar] [Crossref]

11. Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia. Support Care Cancer. 2014;22(3):619–630. [Google Scholar] [Crossref]

12. Gudiol C, Bodro M, Simonetti A, et al. Changing epidemiology of bacteremia in neutropenic patients. Clin Microbiol Infect. 2013;19(5):474–479. [Google Scholar] [Crossref]

13. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in neutropenic patient infections. Clin Infect Dis. 2003;36(9):1103–1110. [Google Scholar] [Crossref]

14. de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO guidelines. Ann Oncol. 2010;21(Suppl 5):v252–v256. [Google Scholar] [Crossref]

15. Klastersky J. Management of fever in neutropenic patients. Ann Oncol. 2004;15(Suppl 4):iv223–iv229. [Google Scholar] [Crossref]

16. Bow EJ. Infection in neutropenic patients with cancer. Crit Care Clin. 2013;29(3):411–441. [Google Scholar] [Crossref]

17. Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2016;14(7):882–913. [Google Scholar] [Crossref]

18. Mikulska M, Viscoli C, Orasch C, et al. Fourth European Conference on Infections in Leukemia guidelines. Lancet Infect Dis. 2014;14(6):495–504. [Google Scholar] [Crossref]

19. Caggiano V, Weiss RV, Rickert TS, et al. Incidence and cost of febrile neutropenia. Cancer. 2005;103(9):1916–1924. [Google Scholar] [Crossref]

20. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy. Lancet Infect Dis. 2013;13(7):575–583. [Google Scholar] [Crossref]

21. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections. Cochrane Database Syst Rev. 2012;1:CD004386. [Google Scholar] [Crossref]

22. Schouten HC, Lokhorst HM, Wittebol S, et al. Outpatient treatment of febrile neutropenia. Eur J Cancer. 2005;41(15):2252–2259. [Google Scholar] [Crossref]

23. Kern WV, Marchetti O, Drgona L, et al. Oral vs intravenous empirical treatment. Clin Infect Dis. 2013;57(4):503–511. [Google Scholar] [Crossref]

24. Freifeld AG. Febrile neutropenia: evolving therapeutic strategies. Clin Infect Dis. 2005;40(Suppl 4):S239–S245. [Google Scholar] [Crossref]

25. Lyman GH. Impact of chemotherapy dose intensity. Oncologist. 2006;11(3):217–223. [Google Scholar] [Crossref]

26. Paul M, Yahav D, Fraser A, et al. Empirical antibiotic monotherapy. J Antimicrob Chemother. 2006;57(2):176–189. [Google Scholar] [Crossref]

• Treasure of 6th Edition of Organon of Medicine- Lm Potency
• Neurobehavioral and Immune-Histochemical Effects of Daucus Carota Ethanolic Leaf Extract in Cadmium-Induced Toxicity of the Hippocampus and Prefrontal Cortex of Adult Wistar Rats
• Unveiling the Antimicrobial Potential of Homoeopathic Sarcode and Bowel Nosode: A Study on Histaminum and Dysenteriae Co against Escherichia Coli And Klebsiella Bacteria
• Incidence of Cardiovascular Events in Patients Receiving Hematopoietic Stem Cell Transplant (HSCT) in HCTM – (A Retrospective Cohort Study)
• A Prospective Case Study Examining the Effectiveness of Homoeopathic Medicine in Treating Degenerative Changes in the Lumbar Spine-A Case Report